Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15063915 | 0.84 | GABRA1 (0.34) | GABRA1GABRB2 | |
| SCHEMBL16320372 | 0.84 | GABRA1 (0.34) | GABRA1GABRB2 | |
| SCHEMBL15063717 | 0.73 | GRIN2D (0.34) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL467893 | 0.73 | GRIN2D (0.34) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28131730 | 0.71 | HTT (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15063876 | 0.71 | GRIN2D (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL455317 | 0.71 | GRIN2D (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15064076 | 0.70 | PTGS2 (0.35) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15063702 | 0.68 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL27907815 | 0.68 | TAAR1 (0.34) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3045450-B1 | INTERMEDIATE COMPOUNDS IN PROCESSES FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2018-02-07 | — | — | EP | disclosed |
| CN-104277004-B | Prepare method and its intermediate of pyridazinone compound | 住友化学株式会社 | 2016-08-24 | — | — | CN | disclosed |
| CN-104326952-B | Prepare method and its intermediate of pyridazinone compound | 住友化学株式会社 | 2016-08-24 | — | — | CN | disclosed |
| EP-3045450-A1 | INTERMEDIATE COMPOUNDS IN A PROCESS FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO., LTD. (JP) | 2016-07-20 | — | — | EP | disclosed |
| EP-2614053-B1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATES THEREOF | SUMITOMO CHEMICAL CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| CN-103180300-B | Process for producing pyridazinone compound and intermediate thereof | SUMITOMO CHEMICAL CO.,LTD. (JP) | 2015-10-07 | — | — | CN | disclosed |
| US-9040709-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-05-26 | — | — | US | disclosed |
| CN-104326952-A | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL CO | 2015-02-04 | — | — | CN | disclosed |
| CN-104277004-A | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL CO | 2015-01-14 | — | — | CN | disclosed |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2014-12-25 | — | — | US | disclosed |
| US-8884010-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| CN-103180300-A | Process for producing pyridazinone compound and intermediate thereof | SUMITOMO CHEMICAL CO | 2013-06-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | GABRA1 2456/4885GABRB2 2331/4885GRIN2D 3166/4885 |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | GABRA1 2456/4885GABRB2 2331/4885GRIN2D 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.